November 11, 2022

Within3 in Journal of mHealth: operational excellence in medical affairs

The time is right for medical affairs to address vulnerabilities in existing operating models and invest in technologies that strengthen the organization.
operational excellence in medical affairs

Perhaps more so than any other part of a life science company, medical affairs organizations are challenged to modernize operations during the pre-launch and launch phases. This modernization is no longer about developing new drugs and treatments for diseases but about how teams can change how they work and achieve operational excellence in medical affairs – leaning on insights management technology to transform how they deliver effective therapies to patients.

In Journal of mHealth, Within3 Channel Partner Director Angela Labrozzi writes about the different factors driving change in the medical affairs role and how medical affairs leaders can prepare for and manage change in their organization.

This modernization is no longer just about developing new drugs and treatments for diseases but about how teams can change how they work and achieve operational excellence.

Labrozzi dives into some of the broader factors facing medical affairs organizations – including ever-increasing amounts of data, new patient preferences, and competitors in emerging markets. “Medical affairs teams have always worked across functions and engaged multiple stakeholders while adhering to rigorous regulatory requirements,” she writes. “Now, they also face a host of new challenges.”

While disruptive forces are pushing medical affairs teams to make significant changes, this challenging environment can be a springboard to drive meaningful change. The time is right for teams to address vulnerabilities in existing operating models and invest in technologies that strengthen the role of medical affairs.

Read the article in the Journal of mHealth.


Related Posts:

AI and the patient voice

Within3 in AIthority

Natural language processing and social listening are transforming various aspects of modern business operations – and life science is no exception.
technology improves trial representation

Within3 in The Pharma Letter: how tech improves trial representation, retention

Trial teams should start with patients in mind for better results along the way.
Insights management in PharmaTimes image depicting lightbulbs

Within3 CEO Lance Hill on insights management in PharmaTimes

How insight gaps contribute to spiraling costs and long timelines – and how an insights management platform solves the problem.